Loading...
01/10 16:58
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several negative indicators: decreased revenue guidance, lower adjusted EBITDA, and a significant tariff impact. The Q&A highlights uncertainties in cash flow and leverage, with management avoiding clear guidance on dividends. Despite some positive developments in orders and demand, the overall sentiment is cautious due to declining margins and backlog, as well as a competitive pricing environment. Given the market cap, the stock is likely to experience a negative reaction in the range of -2% to -8%.
Revenue $599 million, down 24% or 10% on a pro forma basis compared to the prior year, driven by the divestiture of MIME and lower capital equipment volume in APS.
Pro forma adjusted EBITDA $84 million, decreased 28% as productivity and favorable pricing were offset by lower volumes, unfavorable product mix, and inflation.
Pro forma adjusted EBITDA margin 14.1%, decreased 360 basis points, largely due to the impact of lower volume on operating leverage.
GAAP net income $2 million, up from a loss of $249 million in the prior year due to the noncash impairment charge recorded in the hot runner product line in the MTS segment in fiscal year 2024.
Adjusted earnings per share $0.51, decreased 40% versus prior year, primarily due to the divestiture of the MIME business and lower APS volumes.
Adjusted effective tax rate 29.4%, 80 basis points higher than the prior year, primarily due to the geographic mix of income.
Cash flow from operations A use of approximately $2 million in the quarter, primarily due to lower customer advances from decreased order volume.
Capital expenditures $10 million in the quarter.
Dividends paid Approximately $16 million to shareholders through the quarterly dividend.
APS segment revenue $507 million, decreased 11% compared to the prior year, driven by lower volume, partially offset by favorable pricing.
APS segment adjusted EBITDA $80 million, decreased 27% year-over-year, primarily due to lower volume, unfavorable product mix, and inflation, partially offset by productivity and favorable pricing.
APS segment adjusted EBITDA margin 15.8%, down 340 basis points from the prior year, as a result of lower volumes, resulting in fixed cost absorption headwinds.
APS segment backlog $1.57 billion, decreased 10% compared to the prior year, as expected, due to decision delays in larger capital orders amid tariff uncertainty.
MTS segment pro forma revenue $92 million, decreased 2% year-over-year as growth in the hot runner business was offset by a decrease in mold-based sales from the 2024 exit of a low-margin product line.
MTS segment pro forma adjusted EBITDA $18 million, decreased 9% as expected.
MTS segment pro forma adjusted EBITDA margin 19.9%, down 170 basis points year-over-year due to tariffs, partially offset by pricing and productivity.
MTS segment pro forma backlog $55 million, increased 7% year-over-year as a result of increased hot runner and mold-based components demand and was flat sequentially.
Net debt $1.51 billion, with a net debt to pro forma adjusted EBITDA ratio of 3.9x.
Food, Health and Nutrition business: Achieved $30 million in run rate cost synergies from Linxis and FPM acquisitions 20 months post-close, ahead of the original 3-5 year estimate. Launched unified approach of FHN brands and technologies at the iba trade show in Germany, representing over 25% of global revenue.
Geographic expansion: Leveraging legacy Coperion's geographic footprint to enhance cross-selling and system solutions in Food, Health and Nutrition markets.
Debt reduction: Reduced debt by over $300 million through MIME divestiture ($265 million proceeds) and TerraSource sale ($115 million proceeds).
Cost synergies: Achieved $30 million in cost synergies from Linxis and FPM acquisitions ahead of schedule.
Operational flexibility: Refinanced credit facility, pushing next maturity to 2029, and redeemed notes due September 2026.
Portfolio simplification: Completed MIME divestiture and TerraSource sale to focus on higher-margin, higher-growth businesses in Performance Materials and Food, Health and Nutrition markets.
In-region, for-region strategy: Localized supply chain and manufacturing to mitigate tariff impacts and enhance operational efficiency.
Global Macroeconomic Uncertainty: Continued cautious order behavior from customers due to global macroeconomic uncertainty and tariff announcements, leading to delays in project decisions.
Tariff Uncertainty: Tariff uncertainty has resulted in customers delaying investment decisions, particularly in the Advanced Process Solutions (APS) segment, impacting order volumes and backlog.
Lower Capital Equipment Volume: Decline in capital equipment volume in the APS segment, driven by macroeconomic factors and tariff-related delays, affecting revenue and profitability.
Inflation and Unfavorable Product Mix: Inflation and unfavorable product mix have negatively impacted adjusted EBITDA margins, particularly in the APS segment.
Supply Chain Localization Challenges: Efforts to localize supply chains and implement in-region, for-region initiatives to mitigate tariff impacts require significant operational adjustments and investments.
Debt Levels: Despite progress in debt reduction, the company still has a net debt of $1.51 billion, with a net debt to pro forma adjusted EBITDA ratio of 3.9x, which could limit financial flexibility.
Customer Decision Delays: Delays in customer decisions for larger capital investments due to tariff and macroeconomic uncertainties, impacting revenue and backlog.
Short-Cycle Business Volatility: Short-cycle nature of the MTS business means it is highly sensitive to market fluctuations, with recovery dependent on external indices and market activity.
Geographic Mix of Income: Higher adjusted effective tax rate due to geographic mix of income, which could impact net profitability.
Dynamic Operating Environment: The need to continuously optimize cost structures and execute strategic initiatives in response to a dynamic operating environment, adding operational complexity.
Portfolio Simplification and Debt Reduction: Hillenbrand has completed the divestiture of the MIME business and the sale of its minority interest in TerraSource, generating $380 million in net proceeds. These funds were used to reduce debt by over $300 million, strengthening the balance sheet.
Food, Health, and Nutrition (FHN) Business Integration: Achieved $30 million in run rate cost synergies from Linxis and FPM acquisitions 20 months post-close, ahead of the original 3-5 year estimate. Focus is now on realizing commercial synergies through cross-selling and leveraging Coperion's geographic footprint.
Market Positioning: The FHN segment now represents over 25% of global revenue, with a focus on offering full system solutions and leveraging historical strengths in systems capabilities.
Operational Adjustments: Implemented surcharge pricing and adjusted contract terms to address tariff impacts. Progressing on localizing supply chains and shifting inventories to align with in-region, for-region initiatives.
Revenue Guidance: Updated fiscal year 2025 revenue guidance to $2.59 billion to $2.63 billion, up from the previous range of $2.56 billion to $2.62 billion.
Earnings Per Share (EPS) Guidance: Narrowed adjusted EPS guidance range to $2.20 to $2.35, maintaining the midpoint of the previous guidance.
Operating Cash Flow and Capital Expenditures: Full-year operating cash flow is expected to be approximately $60 million, with $40 million allocated for capital expenditures, focusing on in-region, for-region projects.
Advanced Process Solutions (APS) Segment Outlook: Despite a year-over-year decline in capital orders due to tariff uncertainty, recent key order wins and increased market activity provide confidence in Q4 and full-year performance. Backlog of $1.57 billion is expected to recover as macroeconomic conditions stabilize.
Molding Technology Solutions (MTS) Segment Outlook: Pro forma backlog increased 7% year-over-year, driven by demand for hot runner and mold-based components. Short-cycle nature of the business allows for quick recovery and high flow-through to the bottom line when volumes return.
Quarterly Dividend Payment: Paid approximately $16 million to shareholders through quarterly dividend.
The earnings call reveals several negative indicators: decreased revenue guidance, lower adjusted EBITDA, and a significant tariff impact. The Q&A highlights uncertainties in cash flow and leverage, with management avoiding clear guidance on dividends. Despite some positive developments in orders and demand, the overall sentiment is cautious due to declining margins and backlog, as well as a competitive pricing environment. Given the market cap, the stock is likely to experience a negative reaction in the range of -2% to -8%.
The earnings call revealed several concerning factors: a decline in revenue and EBITDA, a net loss, and a high net debt ratio. Despite some positive elements like the sale of TerraSource and achieving synergy targets, market volatility and tariff impacts are significant challenges. The Q&A highlighted order delays and management's lack of clarity on inflation impacts. The company's market cap suggests moderate sensitivity to these issues, leading to a predicted negative stock price movement of -2% to -8%.
The earnings call reveals several challenges: a revenue decline, cost inflation, backlog reduction, and deleveraging issues. Despite some positive developments like the TerraSource sale for debt reduction, the financial performance is weak, with a significant year-over-year decrease in revenue and adjusted EBITDA. The Q&A section highlights management's lack of clarity on tariffs and future orders, further contributing to uncertainty. Given these factors and the company's small-cap status, a negative stock price movement of -2% to -8% is expected.
The earnings call reveals declining financial performance, with year-over-year decreases in revenue, EPS, and EBITDA, compounded by geopolitical and economic uncertainties. Despite some positive updates, such as the Milacron sale proceeds and potential market strength in specific regions, the overall guidance reflects a downward trend. The Q&A section highlights management's evasive responses and ongoing market challenges, which could further dampen investor confidence. Given the company's market cap and the current negative sentiment, a negative stock price movement is anticipated over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
